March 6th 2025
Survey examines experiences and perceptions of patients living with GA.
February 13th 2025
Pegcetacoplan shows increasing beneficial effects after 30 Months of Continuous treatment for GA
August 2nd 2023Data from the 30 month GALE extension study indicated that continuous treatment with pegcetacoplan injection showed increasing beneficial effects over that timeframe in patients with geographic atrophy (GA).
Read More
ASRS Live: Apellis providing update on review of safety events with pegcetacoplan injection for GA
July 30th 2023During presentations at the American Society for Retina Specialists 41st Annual Meeting in Seattle, the company noted that there was no indication that drug product or manufacturing issues contributed to rare events of retinal vasculitis.
Read More
Is complement therapy the path forward for geographic atrophy?
July 17th 2023The complement system identifies and eliminates pathogens and dying cells, 3 pathways can activate the complement system—classical, lectin, and alternative—and their activation results in similar functions of opsonization, inflammation, and cell lysis.
Read More
Annexon announces topline results from ARCHER Phase 2 trial of ANX007 for geographic atrophy
May 29th 2023Data supports ANX007 as the first complement therapy to preserve visual acuity, achieving statistically significant protection, but reduction in rate of geographic atrophy lesion growth did not reach statistical significance.
Read More